EDESA BIOTECH, INC. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
EDESA BIOTECH, INC. (EDSA) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $5.76 per share as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-05-14
- 2014-08-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 1.58 CAD/shares.
- 2013-08-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 0.38 CAD/shares.
- 2012-08-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 0.40 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2014-08-31 | 1.58 CAD/shares 10-K · filed 2014-11-21 |
| 2013-08-31 | 0.38 CAD/shares 10-K · filed 2014-11-21 |
| 2012-08-31 | 0.40 CAD/shares 10-K · filed 2014-11-21 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2026-03-31 | $5.76 10-Q · filed 2026-05-14 |
| 2025-12-31 | $6.21 10-Q · filed 2026-02-13 |
| 2025-09-30 | $6.77 10-K · filed 2025-12-12 |
| 2025-06-30 | $7.00 10-Q · filed 2025-08-08 |
| 2025-03-31 | $7.12 10-Q · filed 2025-05-14 |
| 2024-12-31 | $7.83 10-Q · filed 2025-02-14 |
| 2024-09-30 | $9.24 10-K · filed 2024-12-13 |
| 2024-06-30 | $10.15 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |